Table 1.

Information on studies examined as part of this study.

Analysis	Cohort(s)	Cohort size
Comparison of NAT expression in tumour vs adjacent normal liver tissue and association with survival	TCGA	371 tumour and 50 normal samples
GSEA comparison of top and bottom quartiles of NAA40 expression in LIHC tumours	TCGA; GSE112790.	TCGA 90 samples for top and bottom quartiles; GSE112790 46 samples for top and bottom quartiles
LIHC disease stage	TCGA	50 samples for the adjacent normal group, Stage I consisted of 150 samples, Stage II of 98 samples, and Stage III of 97 samples
Obese and non-obese LIHC patients	TCGA	127 obese patients and 37 non-obese
LIHC patients with cirrhosis vs no cirrhosis	TCGA	47 cirrhotic patients and 140 non-cirrhotic patients
LIHC patients with stages of liver inflammation	TCGA	117 were defined as non-inflamed, 99 as mild inflammation, and 18 as severely inflamed
LIHC patients at different Fibrosis stages	TCGA	97 were classified as stage 0, for stages 1&2 35 samples, stages 3&4 31, stage 5 10 samples, and for stage 6 76 samples
LIHC patients with serological data for Hepatitis B or C infection	TCGA	207 serologically negative for both hepatitis B and C; 84 serologically positive for both hepatitis B and C; 60 positive only for hepatitis B and 19 only for hepatitis C
iCLuster classification	TCGA	65 iCluster 1, 55 iCluster 2, and 63 for iCluster 3
P53 and CTNNB1 mutation cohorts	TCGA	P53 but no CTNNB1 mutations (N=88); CTNNB1 but no P53 mutations (N=71); no identified mutations in either of the two genes (N=171)
Association of NAA40 with survival and P53 activity	GSE14520; GSE54236	GSE14520 221 samples with survival and transcriptomic data; GSE54236 78 samples with survival and transcriptomic data
Hepatic differentiation	GSE23034; GSE61287; GSE19044; GSE73617	GSE23034 compared hepatocytes (N=3) and hepatocyte derived induced pluripotent stem cells (iPSC) (N=3); GSE61287 comparison of hepatocytes, iPSC derived from hepatocytes, and hepatocyte-like cells (HLC) differentiated from the iPSC (N=1 for all groups); GSE19044 Germline cell-derived pluripotent stem cells (GPSCs) and Embryonic stem cells (ES) in naïve state or differentiated into hepatocytes (N=2 all groups); GSE73617 Mesenchymal stromal cells (MSCs), HLC derived from MSC, and HLC induced to dedifferentiate (N=3 each group
P53 manipulation	GSE34760; GSE30137; GSE30137	GSE34760 compared liver tumours derived from p53 KO mice and from p53 wildtype liver tumours induced by N-nitrosodiethylamine (DEN) treatment (N=4-6 per group); GSE30137 HepG2 cells treated with DMSO, shP53, Nutlin, Nutlin+shP53 (N=2 per group); GSE30137 acute knockout of P53 using adenoviral construct (N=3 for GFP control and CRE treatment respectively)
Cancer cell lines	DepMap	Cell lines originating from ten different tissues of origin were examined, ranging from 22-107 cell lines per tissue.